Study to Determine Tolerability of Single Increasing Dose of BIBN 4096 BS in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: BIBN 4096 BS - in single rising dosesDrug: Placebo
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-23
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02194348
Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02194270
Safety, Tolerability and Pharmacokinetics of Single and Multiple Oral Doses of 40 mg Telmisartan/5 mg Amlodipine and 80 mg Telmisartan/5 mg Amlodipine in Healthy Male Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT02194309
Efficacy of a Standardised Bilberry Extract in Improving the Night Vision of Healthy Volunteers
Phase 2
Completed
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: Anthocyan capsules
- First Posted Date
- 2014-07-18
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 119
- Registration Number
- NCT02194361
Bioequivalence of Telmisartan/Amlodipine Fixed Dose Combination Compared With Its Monocomponents in Healthy Male and Female Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-17
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 84
- Registration Number
- NCT02193308
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 32
- Registration Number
- NCT02191891
- Locations
- 🇰🇷
Asan Medical Center, Seoul, Korea, Republic of
🇯🇵National Hospital Organization Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
🇸🇬National Cancer Centre, Singapore, Singapore
Pharmacokinetics of a Single Oral Dose of 1,800 mg Red Vine Leaf Extract (Antistax®)
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Red Vine Leaf Extract
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2018-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT02191241
Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 27
- Registration Number
- NCT02191189
Observational Study in Patients With HIV Infection Type 1 After Switching to a Viramune®-Containing Therapy Regimen
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 147
- Registration Number
- NCT02191332
Antistax® in Patients With Chronic Venous Insufficiency
Phase 2
Completed
- Conditions
- Venous Insufficiency
- Interventions
- Drug: Antistax®, high doseDrug: PlaceboDrug: Antistax®, low dose
- First Posted Date
- 2014-07-16
- Last Posted Date
- 2014-07-16
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 260
- Registration Number
- NCT02191280
© Copyright 2025. All Rights Reserved by MedPath